AR050838A1 - Formulacion farmaceutica. para el tratamiento de una infeccion optica - Google Patents

Formulacion farmaceutica. para el tratamiento de una infeccion optica

Info

Publication number
AR050838A1
AR050838A1 ARP050103355A ARP050103355A AR050838A1 AR 050838 A1 AR050838 A1 AR 050838A1 AR P050103355 A ARP050103355 A AR P050103355A AR P050103355 A ARP050103355 A AR P050103355A AR 050838 A1 AR050838 A1 AR 050838A1
Authority
AR
Argentina
Prior art keywords
optical
treatment
infection
pharmaceutically acceptable
pharmaceutical formulation
Prior art date
Application number
ARP050103355A
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR050838A1 publication Critical patent/AR050838A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen novedosas formulaciones para el tratamiento de las infecciones opticas en un animal, que comprenden un compuesto antifungico de triazol, un antibiotico de quinolona y un corticoesteroide tal como mometasona furoato monohidrato. Reivindicacion 1: Una composicion farmacéutica para el tratamiento de una infeccion optica en un animal, que comprende Orbifloxacina o una de sus sales farmacéuticamente aceptables; una cantidad efectiva como antifungico de un compuesto de triazol farmacéuticamente aceptable, Mometasona Furoato Monohidrato y por lo menos un vehículo farmacéuticamente aceptable, donde dicha composicion es una suspension.
ARP050103355A 2004-08-13 2005-08-11 Formulacion farmaceutica. para el tratamiento de una infeccion optica AR050838A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60147504P 2004-08-13 2004-08-13

Publications (1)

Publication Number Publication Date
AR050838A1 true AR050838A1 (es) 2006-11-29

Family

ID=35431350

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103355A AR050838A1 (es) 2004-08-13 2005-08-11 Formulacion farmaceutica. para el tratamiento de una infeccion optica

Country Status (28)

Country Link
US (2) US8084445B2 (es)
EP (1) EP1776109B1 (es)
JP (2) JP4792032B2 (es)
KR (1) KR101289115B1 (es)
CN (2) CN101039668A (es)
AR (1) AR050838A1 (es)
AT (1) ATE418984T1 (es)
AU (1) AU2005272925B2 (es)
BR (1) BRPI0514098B1 (es)
CA (1) CA2576589C (es)
DE (1) DE602005012107D1 (es)
DK (1) DK1776109T3 (es)
EC (1) ECSP077239A (es)
ES (1) ES2320360T3 (es)
HK (1) HK1098368A1 (es)
IL (1) IL181248A (es)
MX (1) MX2007001811A (es)
MY (1) MY145148A (es)
NO (1) NO20073073L (es)
NZ (1) NZ553119A (es)
PE (1) PE20060489A1 (es)
PL (1) PL1776109T3 (es)
PT (1) PT1776109E (es)
RU (1) RU2394573C2 (es)
TW (1) TWI362261B (es)
UA (1) UA89793C2 (es)
WO (1) WO2006020689A1 (es)
ZA (1) ZA200701253B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012184A1 (en) * 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
US6426342B2 (en) * 1999-08-16 2002-07-30 Revaax Pharmaceuticals, Llc Use of β-lactamase inhibitors as neuroprotectants
US8088820B2 (en) * 2001-04-24 2012-01-03 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds for the treatment of malaria
EP1776109B1 (en) 2004-08-13 2008-12-31 Schering-Plough Ltd. Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid
DE102005055385A1 (de) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Arzneimittel zur hygienischen Applikation im Ohr
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
WO2007129176A2 (en) * 2006-04-28 2007-11-15 Wockhardt Ltd Improvements in therapy for treating resistant bacterial infections
WO2008002118A1 (es) * 2006-06-27 2008-01-03 Arturo Jimenez Bayardo Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
BRPI0703127A2 (pt) * 2007-08-22 2009-04-14 Ouro Fino Participacoes E Empreendimentos Sa composição para o tratamento de otites agudas ou crÈnicas causadas por fungos e/ou bactérias em animais de companhia
EP2214680A4 (en) * 2007-10-26 2010-12-29 Rexahn Pharmaceuticals Inc PHARMACEUTICAL FORMULATION OF CLAVLANIC ACID
PE20091171A1 (es) * 2007-12-14 2009-08-03 Schering Plough Ltd Proceso para recuperar florfenicol y analogos de florfenicol
TW201010708A (en) * 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid
US8318817B2 (en) * 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
CA2758029A1 (en) * 2009-04-29 2011-11-04 Rexahn Pharmaceuticals, Inc. Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
PL3391890T3 (pl) * 2010-06-29 2021-12-20 Merck Sharp & Dohme Corp. Preparaty dożylnego roztworu pozakonazolu stabilizowane podstawioną beta-cyklodekstryną
RU2555509C2 (ru) 2010-12-20 2015-07-10 Колгейт-Палмолив Компани Инкапсулированная в желатине композиция для ухода за полостью рта, содержащая гидрофильный активный ингредиент, гидрофобный структурирующий ингредиент и масляный носитель
JP6117112B2 (ja) * 2011-11-30 2017-04-19 富山化学工業株式会社 １−シクロプロピル−８−（ジフルオロメトキシ）−７−［（１ｒ）−１−メチル−２，３−ジヒドロ−１ｈ−イソインドール−５−イル］−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸のメタンスルホン酸塩水和物含有錠剤
CN104884092A (zh) * 2013-01-14 2015-09-02 沃克哈特有限公司 用于治疗细菌感染的组合物和方法
KR101473979B1 (ko) * 2013-01-18 2014-12-26 한국썸벧(주) 마보플록사신을 포함하는 약제학적 조성물
US9078853B2 (en) 2013-06-18 2015-07-14 Cmpd Licensing, Llc Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders
CN104606141A (zh) * 2013-11-01 2015-05-13 瑞普（天津）生物药业有限公司 一种替米考星肠溶微丸
CN104983718A (zh) * 2015-07-17 2015-10-21 江西博莱大药厂有限公司 一种替米考星缓释微丸及其制备方法和应用
CN105412123B (zh) * 2015-11-06 2018-03-13 山东省千佛山医院 布地奈德联合三唑类抗真菌药物的应用及其产品
WO2017091168A1 (en) 2015-11-28 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. A topical spray comprising isoconazole nitrate and difluocortolone valerate
US11986448B2 (en) 2016-11-17 2024-05-21 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
US11737975B2 (en) 2016-11-17 2023-08-29 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10966946B2 (en) 2016-11-17 2021-04-06 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
CN109096307A (zh) * 2017-06-20 2018-12-28 赵建宇 一种33/4水头孢曲松钠化合物
WO2019126910A1 (zh) * 2017-12-25 2019-07-04 湘北威尔曼制药股份有限公司 含有哌拉西林的组合物、其药物制剂及其应用
WO2021072063A1 (en) * 2019-10-11 2021-04-15 Piedmont Animal Health Inc. Otic formulations, methods and devices
CN111166719A (zh) * 2019-12-31 2020-05-19 郑州都灵兽药科技有限公司 一种泰拉霉素肠溶颗粒的制备方法
CN112089695A (zh) * 2020-10-30 2020-12-18 康普药业股份有限公司 一种头孢克肟颗粒制剂及其制备方法
MX2024007632A (es) 2021-12-20 2024-07-09 Intervet Int B V Una composicion farmaceutica para el tratamiento de infecciones oticas.

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141078A (en) 1975-10-14 1979-02-20 Innovated Systems, Inc. Library circulation control system
US4235892A (en) 1979-02-05 1980-11-25 Schering Corporation, Patent Dept. 1-Aryl-2-acylamido-3-fluoro-1-propanols, methods for their use as antibacterial agents and compositions useful therefor
ES488154A0 (es) 1979-02-05 1981-04-16 Schering Corp Un procedimiento para la preparacion de un compuesto d-(treo-1-aril-2-acilamido-3-fluor-1-propanol
US4458802A (en) 1981-03-03 1984-07-10 K.J.A. Maciver & Sons (Proprietary) Limited Renting of articles and machine thereof
US4820695A (en) 1982-09-13 1989-04-11 Eli Lilly And Company C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics
US4443430A (en) 1982-11-16 1984-04-17 Ethicon, Inc. Synthetic absorbable hemostatic agent
IT1173213B (it) 1984-02-03 1987-06-18 Zambon Spa Procedimento per fluorurare alcuni derivati dall'1l-fenil-2-ammino-1,3-propandiolo e loro intermedi
US5105009A (en) 1983-06-02 1992-04-14 Zambon S.P.A. Intermediates for the preparation of 1-(phenyl)-1-hydroxy-2-amino-3-fluoropropane derivatives
US5332835A (en) 1984-02-03 1994-07-26 Zambon S.P.A. Process for fluorinating 1-phenyl-2-amino-1,3-propanediol compounds and new oxazoline compounds useful in this process
US4973750A (en) 1984-09-19 1990-11-27 Schering Corporation Preparation of (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US4582918A (en) 1984-09-19 1986-04-15 Schering Corporation Preparation of intermediates for (threo)-1-aryl-2-acylamido-3-fluoro-1-propanols
US4812629A (en) 1985-03-06 1989-03-14 Term-Tronics, Incorporated Method and apparatus for vending
US5104868A (en) 1988-06-21 1992-04-14 Pfizer Inc. Tricyclic derivatives of 7-substituted-6-fluoro-1,4-dihydroquinol-4-one-3-carboxylic acids and esters
US5095195A (en) 1988-08-03 1992-03-10 Thru-The-Wall Corporation Automated videocassette dispensing terminal with reservation feature
US5594228A (en) 1988-08-25 1997-01-14 Symbol Technologies, Inc. Self-checkout, point-of-transaction system including deactivatable electro-optically coded surveillance tags
US4876352A (en) 1988-09-14 1989-10-24 Schering Corporation Pressurized fluorination of hydroxy alkyl groups
US5227494A (en) 1988-09-14 1993-07-13 Schering Corporation Process for preparing oxazoline compounds
CA2001203C (en) 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
US5491139A (en) 1988-10-24 1996-02-13 The Procter & Gamble Company Antimicrobial quinolonyl lactams
US5007518A (en) 1989-02-13 1991-04-16 Sam Crivello Apparatus for renting articles
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JPH05506033A (ja) 1990-04-18 1993-09-02 ノーウィッチ、イートン、ファーマスーティカルズ、インコーポレーテッド 抗微生物性キノロニルラクタム類
EP0555340B1 (en) 1990-10-25 1994-12-07 Schering Corporation Process for preparing florfenicol, its analogs and oxazoline intermediates thereto
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5646163A (en) 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
US5352832A (en) 1992-12-18 1994-10-04 Schering Corporation Asymmetric process for preparing florfenicol, thiamphenicol chloramphenicol and oxazoline intermediates
KR0148277B1 (ko) 1993-01-18 1998-11-02 채영복 신규한 플루오르퀴놀론계 유도체 및 그의 제조방법
AU4272793A (en) 1993-04-24 1994-11-21 Korea Research Institute Of Chemical Technology Novel quinolone carboxylic acid derivatives and process for preparing the same
CA2168764C (en) 1993-08-13 2000-01-18 Sung June Yoon Novel quinolone carboxylic acid derivatives
FR2711524B1 (fr) 1993-10-21 1995-11-24 Rhone Dpc Europ Procédé de préparation de compositions orales contenant des quinolones.
WO1995012870A1 (en) 1993-11-04 1995-05-11 Knogo Corporation Method and apparatus for automatically desensitizing sensor elements
US5661151A (en) * 1993-12-21 1997-08-26 Schering Corporation Tetrahydrofuran antifungals
AU681753B2 (en) * 1993-12-21 1997-09-04 Merck Sharp & Dohme Corp. Tetrahydrofuran antifungals
AU709057B2 (en) 1994-11-18 1999-08-19 Pharmacia & Upjohn Company A new physically stable solid form of a fluoroquinolone
US5777884A (en) 1995-10-16 1998-07-07 Minnesota Mining And Manufacturing Company Article inventory tracking and control system
US5834472A (en) 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
US5663361A (en) 1996-08-19 1997-09-02 Schering Corporation Process for preparing intermediates to florfenicol
US5990794A (en) * 1996-09-26 1999-11-23 Sensormatic Electronics Corporation Apparatus for data communication and deactivation of electronic article surveillance tags
JP3892085B2 (ja) 1996-10-04 2007-03-14 東興薬品工業株式会社 動物用点耳クリーム剤
US6025780A (en) 1997-07-25 2000-02-15 Checkpoint Systems, Inc. RFID tags which are virtually activated and/or deactivated and apparatus and methods of using same in an electronic security system
JP2001520188A (ja) * 1997-10-22 2001-10-30 ポニカウ，ジェンス 粘膜組織の炎症を治療および予防するための方法ならびに物質
ATE376232T1 (de) * 1998-08-14 2007-11-15 3M Innovative Properties Co Anwendungen für radiofrequenzidentifikationssysteme
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
US6169483B1 (en) 1999-05-04 2001-01-02 Sensormatic Electronics Corporation Self-checkout/self-check-in RFID and electronics article surveillance system
US6333692B1 (en) 1999-07-06 2001-12-25 Ats Money Systems Inc. Security tag deactivation system
US20020067267A1 (en) * 2000-03-15 2002-06-06 Richard Kirkham Package identification system
CN1137899C (zh) 2000-03-16 2004-02-11 上海华联制药有限公司 17,21-酯取代的1,4-二烯-3-酮-9,11-环氧甾体化合物
AU2001261748A1 (en) 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose
CA2412376A1 (en) * 2000-07-26 2002-01-31 Onkar N. Singh Pharmaceutical suspension compositions lacking a polymeric suspending agent
JP4104463B2 (ja) 2001-04-27 2008-06-18 ファイザー・プロダクツ・インク ４’’−置換された−９−デオキソ−９ａ−アザ−９ａ−ホモエリスロマイシン誘導体を製造するための方法
ES2250739T3 (es) * 2001-09-21 2006-04-16 Alcon, Inc. Metodo para tratar infecciones del oido medio.
BR0314763A (pt) 2002-09-23 2005-07-26 Schering Corp Tratamento de infecções fúngicas
US20050159369A1 (en) * 2003-08-20 2005-07-21 Qtm Llc Method of treatment of otitis externa
EP1776109B1 (en) 2004-08-13 2008-12-31 Schering-Plough Ltd. Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid
TW201010708A (en) 2008-06-02 2010-03-16 Intervet Int Bv Composition comprising an antibiotic and a corticosteroid

Also Published As

Publication number Publication date
KR20070041571A (ko) 2007-04-18
ECSP077239A (es) 2007-03-29
DE602005012107D1 (de) 2009-02-12
CN102499928A (zh) 2012-06-20
ZA200701253B (en) 2008-07-30
RU2007108875A (ru) 2008-09-20
CA2576589C (en) 2013-11-12
US8084445B2 (en) 2011-12-27
EP1776109A1 (en) 2007-04-25
AU2005272925B2 (en) 2011-02-10
UA89793C2 (uk) 2010-03-10
US8609645B2 (en) 2013-12-17
US20060122159A1 (en) 2006-06-08
BRPI0514098A (pt) 2008-05-27
JP2011178811A (ja) 2011-09-15
NZ553119A (en) 2010-11-26
BRPI0514098B1 (pt) 2021-01-19
JP4792032B2 (ja) 2011-10-12
ES2320360T3 (es) 2009-05-21
IL181248A0 (en) 2007-07-04
MX2007001811A (es) 2007-03-26
CN101039668A (zh) 2007-09-19
AU2005272925A1 (en) 2006-02-23
IL181248A (en) 2014-07-31
TWI362261B (en) 2012-04-21
KR101289115B1 (ko) 2013-07-23
NO20073073L (no) 2007-06-15
JP2008509913A (ja) 2008-04-03
CA2576589A1 (en) 2006-02-23
EP1776109B1 (en) 2008-12-31
MY145148A (en) 2011-12-30
HK1098368A1 (en) 2007-07-20
PE20060489A1 (es) 2006-06-19
RU2394573C2 (ru) 2010-07-20
TW200621238A (en) 2006-07-01
US20120058964A1 (en) 2012-03-08
DK1776109T3 (da) 2009-05-04
PL1776109T3 (pl) 2009-06-30
PT1776109E (pt) 2009-03-25
ATE418984T1 (de) 2009-01-15
WO2006020689A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
AR050838A1 (es) Formulacion farmaceutica. para el tratamiento de una infeccion optica
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
WO2006048747A8 (en) Topical pharmaceutical compositions containing an antiacne compound and antibiotic compound
UY28510A1 (es) Compuestos quimicos
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
CY1109117T1 (el) Διαμορφωσεις enaιωphmatoς, οι οποιες περιλαμβανουν δραστικον συστατικο, επιφανειακως δρωσαν ουσια poloxamer ή meroxapol και γλυκολη, χρησις του δια την βιομηχανικην παρασκευην φαρμακου προς νοσηλειαν οφθαλμικων διαταραχων
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
DE602004024375D1 (de) Carboxamidderivate
TW200700392A (en) Novel compounds
ZA200709296B (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycolotonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
ATE386725T1 (de) Heterocyclylverbindungen
AR029226A1 (es) Tioamidas, composiciones farmaceuticas y el uso de la misma para la fabricacion de compuestos medicinales
EA200400086A1 (ru) Новые производные оксазолидинонов в качестве антибактериальных агентов
DE602004012269D1 (de) Quervernetzte glycopeptid-cephalosporin-antibiotika
SE0101932D0 (sv) Pharmaceutical combinations
DE602004024393D1 (de) Quervernetzte glycopeptid-cephalosporin-antibiotika
AR064152A1 (es) Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion.
AR054888A1 (es) Derivados de quinolina como agentes antibacterianos
UY29402A1 (es) Composiciones antifúngicas
ECSP055625A (es) Profarmaco inhibidor de beta-lactamasa
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
RS51615B (en) PHOTOSTABLE PHARMACEUTICAL COMPOSITION CONTAINING BRIVUDINE FOR THE TREATMENT OF HERPETIC KERATITIS
ECSP045405A (es) Penems 6-alquiliden heterotriciclil como inhibidores de la beta lactamasa
WO2002055022A3 (en) Active metabolite of antifungal compound

Legal Events

Date Code Title Description
FC Refusal